404 related articles for article (PubMed ID: 30615227)
1. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis.
Liu J; Ma B; Cao W; Li M; Bramer WM; Peppelenbosch MP; Pan Q
Transpl Infect Dis; 2019 Apr; 21(2):e13047. PubMed ID: 30615227
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis.
Suwanthawornkul T; Anothaisintawee T; Sobhonslidsuk A; Thakkinstian A; Teerawattananon Y
PLoS One; 2015; 10(12):e0145953. PubMed ID: 26720298
[TBL] [Abstract][Full Text] [Related]
3. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
[TBL] [Abstract][Full Text] [Related]
4. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Beinhardt S; Al-Zoairy R; Kozbial K; Stättermayer AF; Maieron A; Stauber R; Strasser M; Zoller H; Graziadei I; Rasoul-Rockenschaub S; Trauner M; Ferenci P; Hofer H
Liver Int; 2018 Jul; 38(7):1188-1197. PubMed ID: 29197145
[TBL] [Abstract][Full Text] [Related]
6. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
Ji F; Wei B; Yeo YH; Ogawa E; Zou B; Stave CD; Li Z; Dang S; Furusyo N; Cheung RC; Nguyen MH
Aliment Pharmacol Ther; 2018 Mar; 47(5):550-562. PubMed ID: 29327780
[TBL] [Abstract][Full Text] [Related]
7. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
Liu CH; Su TH; Liu CJ; Hong CM; Yang HC; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2019 Sep; 34(9):1620-1625. PubMed ID: 30693965
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.
Yosry A; Gamal Eldeen H; Medhat E; Mehrez M; Zayed N; Elakel W; Abdelmoniem R; Kaddah M; Abdelaziz A; Esmat G; El-Serafy M; Doss W
J Med Virol; 2019 Apr; 91(4):668-676. PubMed ID: 30549048
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
Sanchez Antolin G; Testillano M; Pascasio JM; Narvaez Rodriguez I; Prieto M; Otero A; Herrero JI; Londoño M; Fernandez Vazquez I; Castells L;
Transplant Proc; 2016 Nov; 48(9):3013-3016. PubMed ID: 27932134
[TBL] [Abstract][Full Text] [Related]
10. Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.
Naguib GG; Farid A; Hassan M; Elshafie A; Shazly YE; Shaker MK; Ezzat H; Safwat E; Ahmed OA; Dabbous H; Sherief AF; Hassany M; Elserafy M; Elsayed MH
Arab J Gastroenterol; 2021 Dec; 22(4):285-291. PubMed ID: 34531135
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
12. Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.
Del Rio-Valencia JC; Asensi-Diez R; Villalobos-Torres L; Muñoz Castillo I
Rev Esp Quimioter; 2018 Jun; 31(3):226-236. PubMed ID: 29771105
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
Zheng YX; Ma SJ; Xiong YH; Fan XG
J Gastroenterol Hepatol; 2020 Sep; 35(9):1477-1487. PubMed ID: 32246857
[TBL] [Abstract][Full Text] [Related]
14. A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil.
Silva IPL; Batista AD; Lopes EP; Filgueira NA; Carvalho BT; Santos JC; Medeiros TB; Melo CRL; Lima MS; Lima K; Lacerda C; Lacerda HR
Rev Inst Med Trop Sao Paulo; 2021; 63():e6. PubMed ID: 33533809
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience.
Araujo A; Valenzuela-Granados V; Lopes AB; Michalczuk MT; Mantovani A; Alvares-da-Silva MR
Ann Hepatol; 2019; 18(3):450-455. PubMed ID: 31028014
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil.
Cheinquer H; Sette H; Wolff FH; de Araujo A; Coelho-Borges S; Soares SRP; Barros MFA
Ann Hepatol; 2017; 16(5):727-733. PubMed ID: 28809742
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Lionetti R; Calvaruso V; Piccolo P; Mancusi RL; Mazzarelli C; Fagiuoli S; Montalbano M; Lenci I; Carrai P; Guaraldi G; Visco-Comandini U; Milana M; Biolato M; Loiacono L; Valente G; Craxì A; Angelico M; D'offizi G
Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193356
[TBL] [Abstract][Full Text] [Related]
18. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.
Crespo J; Calleja JL; Fernández I; Sacristan B; Ruiz-Antorán B; Ampuero J; Hernández-Conde M; García-Samaniego J; Gea F; Buti M; Cabezas J; Lens S; Morillas RM; Salcines JR; Pascasio JM; Turnes J; Sáez-Royuela F; Arenas J; Rincón D; Prieto M; Jorquera F; Sanchez Ruano JJ; Navascués CA; Molina E; Moya AG; Moreno-Planas JM;
Clin Gastroenterol Hepatol; 2017 Jun; 15(6):945-949.e1. PubMed ID: 28238958
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.
Gutierrez JA; Carrion AF; Avalos D; O'Brien C; Martin P; Bhamidimarri KR; Peyton A
Liver Transpl; 2015 Jun; 21(6):823-30. PubMed ID: 25825070
[TBL] [Abstract][Full Text] [Related]
20. Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis.
Liao HT; Tan P; Huang JW; Yuan KF
Transplant Proc; 2017 Oct; 49(8):1855-1863. PubMed ID: 28923637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]